Markers matrix metalloproteinases

Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer prognostic markers and therapeutic targets. Int J Cancer 99 157-166... 

Markers of systemic inflammation (e.g., C-reactive protein [CRP] and interleukin-6 [IL-6]) have been proposed to be nontradi-tional risk factors for cardiovascular disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of atherosclerotic plaque rupture, which raises the possibility of the use of MMP-9 levels as a marker for future MI or UA. In vitro and animal studies suggest that thiazolidinediones can reduce the expression of these markers. Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk. The management of UA and NSTEMI is covered in detail in Chap. 16. 

Gl. Galboiz, Y., Shapiro, S., Lahat, N., Rawashdeh, H., and Miller, A., Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50, 443-451 (2001). 

M9. Matsuyama, A., Sakai, N., Ishigami, M., et at. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 108, 1469-1473 (2003). 

V6. Vuoristo, M. S., Kellokumpu-Lehtinen, P., Parvinen, L. M., Hahka-Kemppinen, M., Korpela, M., Kumpulainen, E., and Laine, S., Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol. 39, 877-879 (2000). Walsh, K. M., Timms, P., Campbell, S., MacSween, R. N., and Morris, A. J., Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloprotei-nases-1 and-2 (TlMP-1 and TlMP-2) as noninvasive markers of hver disease in chronic hepatitis C Comparison using ROC analysis. Dig. Dis. Sci. 44, 624-630 (1999). 

Y7. Yoshikawa, T., Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 86, 1929-1935 (1999). 

Fig. 4 In situ zymography and immunohistochemistry of MMPs Relationship with BBB disruption induced by HIV-1 gpl 20. (a) Injection of gpl 20 into the rat CP induced upregulation of matrix metalloproteinases (MMPs). Frozen cryostat sections of CP injected with 500 ng gpl 20 and stained by in situ zymography. Left column The fluorescent product was observed in blood vessel-like structures and in cells. Middle column-. Positive control. In situ zymography detects intense fluorescence in the hippocampus. Right coiumrr. No gelatinolytic activity was seen In the contralateral unInjected side or in CPs injected with saline (not shown), neither when a section of the test brain was incubated with 1,10-phenanthroline, a nonspecific inhibitor of MMP activity, (b) There was a colocalization between In situ zymography and RECA-1. (c) Colocalization between MMP-2 and the endothelial cell marker RECA-1 In CPs Injected with gpl 20. MMP abnormalities were associated with EB leakage (not shown in this panel) (modified from [25,48,105])...

Y5. Ylisirnio, S., Hoyhtya, M., and Turpeenniemi-Hujanen, T., Serum matrix metallo-proteinases-2, -9, and tissue inhibitors of metalloproteinases-1, -2 in lung cancer— TlMP-1 as a prognostic marker. Anticancer Res. 20, 1311-1316 (2000). 

---